Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
A dynamic characterization of the blood metabolome for the prediction of tumor onset in Li-Fraumeni syndrome
EF 2021-22
Résumé
Li-Fraumeni Syndrome (LFS) is a genetic condition which drastically increases the risk of developing a spectrum of early-onset cancers. 1 in 5000 people are affected by LFS, and 80% of LFS patients are diagnosed with cancer before age 50. The Hospital for Sick Children has developed a surveillance protocol for the early detection of tumors in LFS patients worldwide; however, the success of this protocol is hindered by variations in patient presentation, including age of tumor onset. Furthermore, endless cycles of screening impose an immense psychosocial burden on patients throughout their lives. While strides have been made in treating LFS cancers once they develop, there remains an important clinical need for better prediction of tumor onset in order to improve treatment outcomes.
Recent evidence suggests that metabolism may be altered in LFS, and there is abundant evidence showing that targeting metabolism may provide new strategies for cancer treatment. For example, metformin, a commonly prescribed diabetes drug, has been associated with lower cancer risk, and one study identified changes in the blood profiles of LFS patients who were treated with metformin. While it is well known that blood harbours a wealth of dynamic information which can be used to monitor disease, dynamic changes in the blood metabolomes of LFS patients have not been studied. To this end, we hypothesize that the blood metabolome can be characterized to predict tumor onset in LFS.
To address this hypothesis, I will be longitudinally profiling the blood metabolomes of pediatric LFS patients and mice, both treated and untreated with metformin. This dynamic information will be integrated to understand whether tumor onset can be predicted using patients' blood. Overall, this work will address the need for a better understanding of the physiology of tumor development in LFS.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
458334
Name
Psarianos Pamela
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
A dynamic characterization of the blood metabolome for the prediction of tumor onset in Li-Fraumeni syndrome
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Biology; Biomarkers; Cancer; Genetics; Metabolism; Metabolomics; Metformin; Pediatrics
Abstract
Li-Fraumeni Syndrome (LFS) is a genetic condition which drastically increases the risk of developing a spectrum of early-onset cancers. 1 in 5000 people are affected by LFS, and 80% of LFS patients are diagnosed with cancer before age 50. The Hospital for Sick Children has developed a surveillance protocol for the early detection of tumors in LFS patients worldwide; however, the success of this protocol is hindered by variations in patient presentation, including age of tumor onset. Furthermore, endless cycles of screening impose an immense psychosocial burden on patients throughout their lives. While strides have been made in treating LFS cancers once they develop, there remains an important clinical need for better prediction of tumor onset in order to improve treatment outcomes.
Recent evidence suggests that metabolism may be altered in LFS, and there is abundant evidence showing that targeting metabolism may provide new strategies for cancer treatment. For example, metformin, a commonly prescribed diabetes drug, has been associated with lower cancer risk, and one study identified changes in the blood profiles of LFS patients who were treated with metformin. While it is well known that blood harbours a wealth of dynamic information which can be used to monitor disease, dynamic changes in the blood metabolomes of LFS patients have not been studied. To this end, we hypothesize that the blood metabolome can be characterized to predict tumor onset in LFS.
To address this hypothesis, I will be longitudinally profiling the blood metabolomes of pediatric LFS patients and mice, both treated and untreated with metformin. This dynamic information will be integrated to understand whether tumor onset can be predicted using patients' blood. Overall, this work will address the need for a better understanding of the physiology of tumor development in LFS.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Psarianos, Pamela
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~